Stock Financial Ratios, Dividends, Split History

CCS / Century Communities Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)900.34
Enterprise Value ($M)1,636.11
Book Value / Share24.83
Price / Book1.25
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 24,555,509
Common Stock Shares Outstanding 29,502,624
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 24,280,871
Common Shares Outstanding 29,616,597
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.05
Return on Equity (ROE)0.11
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Net Income50.30
Cash Flow Statement (mra) ($M)
Cash From Operations-114.65
Cash from Investing-134.45
Cash from Financing-134.45
Identifiers and Descriptors
Central Index Key (CIK)1576940

Split History

Stock splits are used by Century Communities Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Toll Brothers (TOL) Q2 Earnings Top, High Cost Hurts Margin

2018-05-23 zacks
Shares of Toll Brothers, Inc. (TOL - Free Report) declined more than 9% on May 22 despite reporting better-than-expected results in the second quarter of fiscal 2018. The country’s leading luxury homes builder reported adjusted earnings of 79 cents per share (adjusted for asset impairment costs) in the second quarter of fiscal 2018, beating the Zacks Consensus Estimate of 76 cents. Without the adjustment, the homebuilder reported earnings of 72 cents per share compared with 73 cents a year ago. (1-0) featured highlights include: Ternium, MSA, Century Communities, Expeditors International and Bryn Mawr

2018-05-23 zacks
Chicago, IL – May 23, 2018 - Stocks in this week’s article Ternium S.A. (TX - Free Report) , MSA Safety Inc. (MSA - Free Report) , Century Communities, Inc. (CCS - Free Report) , Expeditors International of Washington, Inc. (EXPD - Free Report) and Bryn Mawr Bank Corporation (BMTC - Free Report) . (29-0)

Dig Into Driehaus Strategy With These 5 Momentum Stocks

2018-05-22 zacks
Driehaus strategy is an investment approach developed by Richard Herman Driehaus using the "buy high and sell higher" principle. This strategy can be used by investors with high-risk appetite by investing mainly in momentum stocks. The success of this investment approach helped Driehaus secure a name in Barron’s All-Century Team. (39-0)

Akamai, American International , Walmart, Amazon and Kroger as Zacks Bull and Bear of the Day

2018-05-22 zacks
Chicago, IL – May 22, 2018 – Zacks Equity Research highlights Akamai Technologies (AKAM - Free Report) as the Bull of the Day and American International Group (AIG - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Walmart (WMT - Free Report) , Amazon (AMZN - Free Report) and Kroger (KR - Free Report) . (113-0)

The Zacks Analyst Blog Highlights: Marathon Oil, Cenovus, Kinder Morgan, TransCanada and Enbridge

2018-05-22 zacks
Chicago, IL – May 22, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Marathon Oil Corp. (MRO - Free Report) , Cenovus Energy Inc. (CVE - Free Report) , Kinder Morgan, Inc. (KMI - Free Report) , TransCanada Corporation (TRP - Free Report) and Enbridge Inc. (67-0)

CUSIP: 156504300